Modulyn Journal References

• 01. Abilify® Prescribing Information
• 02. Effects of ipsapirone and cannabidiol on human experimental anxiety.
• 03. Quality of life in schizophrenic patients.
• 04. Hypnotic and Antiepileptic Effects of Cannabidiol.
• 05. Effects of cannabidiol (CBD) on regional cerebral blood flow.
• 06. Dosing Atypical Antipsychotics.
• 07. Modern antipsychotic drugs: a critical overview.
• 08. The economic burden of schizophrenia in Canada in 2004.
• 09. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum.
• 10. Antianxiety effect of cannabidiol in the elevated plus-maze.
• 11. Psychotropic medications around the world.
• 12. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice.
• 13. Cannabidiol: an overview of some pharmacological aspects.
• 14. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.
• 15. How do we choose between atypical antipsychotics? The advantages of amisulpride.
• 16. A Report on Mental Illnesses in Canada. Chapter 3: Schizophrenia.
• 17. Side effects as influencers of treatment outcome.
• 18. Efficacy of newer generation antipsychotics in the treatment of schizophrenia.
• 19. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.
• 20. Effects of cannabidiol in animal models predictive of antipsychotic activity.
• 21. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Literature

01. Abilify® Prescribing Information

(2008) Otsuka Pharmaceutical Company, Ltd., Tokyo, Japan.

Link to PDF

02. Effects of ipsapirone and cannabidiol on human experimental anxiety.

Zuardi AW, Cosme RA, Graeff FG, and Guimarães FS.

Journal of Psychopharmacology. (1993) 7(1): 82-88.

Link to abstract

03. Quality of life in schizophrenic patients.

Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousoño M.

Dialogues Clin Neurosci. (2007) 9(2): 215-26.

Link to abstract

04. Hypnotic and Antiepileptic Effects of Cannabidiol.

Carlini EA, Cunha JM.

J Clin Pharmacol. (1981) 21(8-9 Suppl): 417S-427S.

Link to abstract

05. Effects of cannabidiol (CBD) on regional cerebral blood flow.

Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G.

Neuropsychopharmacology. (2004) 29(2): 417-26.

Link to article

06. Dosing Atypical Antipsychotics.

Cutler A, Ball S, Stahl SM.

CNS Spectrums. (2008) 13(5 Suppl 9):1-16.

Link to article

07. Modern antipsychotic drugs: a critical overview.

Gardner DM, Baldessarini RJ, Waraich P.

CMAJ. (2005) 172(13): 1703-11.

Link to article

08. The economic burden of schizophrenia in Canada in 2004.

Goeree R, Farahati F, Burke N, Blackhouse G, O'Reilly D, Pyne J, Tarride JE.

Curr Med Res Opin. (2005) 21(12): 2017-28.

Link to abstract

09. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum.

Guimarães VM, Zuardi AW, Del Bel EA, Guimarães FS.

Life Sciences. (2004) 75(5): 633-8.

Link to abstract

10. Antianxiety effect of cannabidiol in the elevated plus-maze.

Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW.

Psychopharmacology (Berl). (1990) 100(4): 558-9.

Link to abstract

11. Psychotropic medications around the world.

Kaplan A.

Psychiatric Times. Vol 21, No. 5. (2004)

Link to article

12. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice.

Long LE, Malone DT, Taylor DA

Neuropsychopharmacology. (2006) 31(4): 795-803.

Link to article

13. Cannabidiol: an overview of some pharmacological aspects.

Mechoulam R, Parker LA, Gallily R.

Journal of Clinical Pharmacology. (2002) 42(11 Suppl): 11S-19S.

Link to abstract

14. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.

Moreira FA, Guimarães FS.

European Journal of Pharmacology. (2005) 512(2-3): 199-205.

Link to abstract

15. How do we choose between atypical antipsychotics? The advantages of amisulpride.

Mortimer, AM.

International Journal of Neuropsychopharmacology. (2004) 7 (Suppl 1): S21–S25.

Link to abstract

16. A Report on Mental Illnesses in Canada. Chapter 3: Schizophrenia.

Public Health Agency of Canada.

(2002)
(Retrieved on Sept. 30, 2008.)

Link to article

17. Side effects as influencers of treatment outcome.

Sharif, Z.

J Clin Psychiatry. (2008) 69 (suppl 3): 38-43.

Link to abstract

18. Efficacy of newer generation antipsychotics in the treatment of schizophrenia.

Tandon R, Jibson MD.

Psychoneuroendocrinology. (2003) 28(Suppl 1): 9-26.

Link to abstract

19. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.

Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, Nomikos GG, Giros B.

Biological Psychiatry. (2006) 59(6): 508-15.

Link to abstract

20. Effects of cannabidiol in animal models predictive of antipsychotic activity.

Zuardi AW, Rodrigues JA, Cunha JM.

Psychopharmacology (Berl). (1991) 104(2): 260-4.

Link to abstract

21. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS.

Brazilian Journal of Medical and Biological Research. (2006) 39(4): 421-9.

Link to article